Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

373.04 +1.48 (+0.40%)
Delayed Quote Updated: 11:23 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript ↗
BRUKINSA revenue surged 31% while management raised full-year guidance by $300 million. 
Via The Motley Fool
Topics Earnings
News headline image
BeOne Medicines Q2 Earnings Call Highlights ↗
BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued... 
Via MarketBeat
Topics Earnings
News headline image
A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position ↗
Executed under pre-established trading plan, this sale reduces the chief executive's direct holdings by just 2%. 
Via The Motley Fool
Topics Regulatory Compliance
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini's SEPA Screen with Strong Technicals and High Growth Momentum ↗
Via Chartmill
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Where BeOne Medicines Stands With Analysts ↗
 
Via Benzinga
News headline image
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 ↗
BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company... 
Via MarketBeat
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials. 
Via The Motley Fool
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Analyst Expectations For BeOne Medicines's Future ↗
 
Via Benzinga
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half ↗
Futu Holdings delivers digital brokerage and wealth management solutions to retail and institutional clients across Asia and global markets. 
Via The Motley Fool
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗
Don't just buy these stocks. Hold onto them. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model ↗
Baidu is transitioning from a search-driven advertising company into an AI infrastructure and enterprise cloud provider in China. HHLR’s exit comes as investors weigh whether this transformation will... 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Prediction: These 3 Stocks Will Crush the Market in 2026 ↗
These stocks all have catalysts on the way that could provide great news for investors. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Stocks to Buy in February ↗
These three stocks appear to be poised for strong performances in 2026. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features ↗
  BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating... 
Via Benzinga
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA. 
Via Investor's Business Daily
Topics Economy Government
News headline image
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions. 
Via Benzinga
News headline image
Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally ↗
Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What's Going On With Summit Therapeutics Stock On Monday? ↗
Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025. 
Via Benzinga
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio? ↗
These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
Via Benzinga
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.